AU1282099A - Method for treatment of disorders of attention - Google Patents

Method for treatment of disorders of attention

Info

Publication number
AU1282099A
AU1282099A AU12820/99A AU1282099A AU1282099A AU 1282099 A AU1282099 A AU 1282099A AU 12820/99 A AU12820/99 A AU 12820/99A AU 1282099 A AU1282099 A AU 1282099A AU 1282099 A AU1282099 A AU 1282099A
Authority
AU
Australia
Prior art keywords
disorders
attention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12820/99A
Inventor
Bonnie M. Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BONNIE M DAVIS
Original Assignee
BONNIE M DAVIS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BONNIE M DAVIS filed Critical BONNIE M DAVIS
Publication of AU1282099A publication Critical patent/AU1282099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU12820/99A 1997-10-29 1998-10-27 Method for treatment of disorders of attention Abandoned AU1282099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6276997P 1997-10-29 1997-10-29
US60062769 1997-10-29
PCT/US1998/022777 WO1999021561A1 (en) 1997-10-29 1998-10-27 Method for treatment of disorders of attention

Publications (1)

Publication Number Publication Date
AU1282099A true AU1282099A (en) 1999-05-17

Family

ID=22044679

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12820/99A Abandoned AU1282099A (en) 1997-10-29 1998-10-27 Method for treatment of disorders of attention

Country Status (2)

Country Link
AU (1) AU1282099A (en)
WO (1) WO1999021561A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
WO2000038686A1 (en) 1998-12-24 2000-07-06 Janssen Pharmaceutica N.V. Controlled release galantamine composition
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP5504253B2 (en) * 2008-04-14 2014-05-28 ニューロダイン ライフ サイエンス インコーポレイテッド Galantamine derivatives as prodrugs for the treatment of human brain disease
CN102625700A (en) * 2009-07-23 2012-08-01 夏尔有限责任公司 Galantamine amino acid and peptide prodrugs and uses thereof
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155226A (en) * 1991-02-19 1992-10-13 Hoechst-Roussel Pharmaceuticals Incorporated Method for the preparation of 9-amino-1,2,3,4-tetrahydroacridine

Also Published As

Publication number Publication date
WO1999021561A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AU4880197A (en) Method for treatment of dermatological disorders
AU9028798A (en) Method of improving drug treatment
AU6578998A (en) Method of treatment of migraine
AU9035498A (en) Method for treating pain
AUPN271295A0 (en) Method of treatment
AU7600198A (en) Formation treatment method using deformable particles
AU2972497A (en) Treatment of oils
AU3977700A (en) Method of treating neurological disorders
AU2058697A (en) Treatment of sleep disorders
AU3784999A (en) Methods for treatment of pain
AU3596797A (en) Methods for the treatment of apolipoprotein e related diseases
AU2251897A (en) Method of treating liver disorders
AU5198898A (en) Method for treatment of glutamate related disorders
AU1282099A (en) Method for treatment of disorders of attention
AU9034798A (en) Method for treating pain
AU5713196A (en) Method for treatment of pain
AU4027097A (en) Method of treatment
AU5855899A (en) Method for identifying substances for the treatment of c-jun-mediated disorders
AU2874497A (en) Balanites aegyptiaca method of treatment
AU4598400A (en) Method of treatment
AU7658098A (en) Method for treatment of an article
AUPP110197A0 (en) Method of treatment
AUPP045397A0 (en) Method of treatment
AUPO582097A0 (en) Method of treatment
AU2003204277A1 (en) Treatment of hematologic disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase